Regeneron Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Regeneron Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Regeneron Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Regeneron Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreBusiness Description
Regeneron Pharmaceuticals Inc (Regeneron) is a biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. Its medicines and pipeline drugs target therapeutic areas such as eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The company’s product portfolio includes Aflibercept injection, dupilumab, cemiplimab injections, evinacumab injections, odronextamab, linvoseltamab, atoltivimab, maftivimab, and odesivimab Injection and rilonacept Injection among others. The company markets its products under the brands name of ltibodies, ARCALYST, Evkeeza, EYLEA, EYLEA HD, Inmazeb, Libtayo, Lynozyfic, Ordspono, Praluent, REGEN-COV, Regeneron, Regeneron Genetics Center, RGC, STEM-Fueled, Veloci-Bi, VelociGene, VelociHum and VelociMab.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Regeneron's R&D arm focuses on initiatives across multiple therapeutic areas, including immunology and inflammation, cancer, hematology, neurology, cardiovascular and metabolic diseases, and rare diseases. The company leverages its proprietary VelociSuite technologies and the Regeneron Genetics Center to advance its R&D efforts. These technologies enable the discovery, development, and production of fully human antibodies, bispecific antibodies, and other innovative therapeutic approaches. The company also focuses on genetic medicine platforms to potentially treat or cure diseases. The R&D unit of Regeneron includes the Regeneron Genetics Center, which plays a crucial role in leveraging clinical, genomic, and proteomic data to identify medically relevant associations and advance innovation in clinical care design. The company also leverage VelociSuite to produce new classes of bispecific antibodies, antibody-protein fusions, and antibody conjugates. Additionally, It use genetic medicine platforms as complementary approaches to these core technologies to potentially treat or cure diseases. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. The company’s Phase-1 pipeline products includes 27T51, ALN-5288, ALN-APOC3, ALN-CIDEB, and REGN5837 among others. Its phase 2 products includes ALN-ANG3, CEMIPLIMAB, DAVUTAMIG , FIANLIMAB, LINVOSELTAMAB and MIBAVADEMAB. The center collaborates with over 150 academic and clinical partners worldwide to expand the use of human genetics in drug discovery and development. Regeneron holds an ownership interest in thousands of patent applications in the United States and other countries. The company's pipeline includes 56 items currently undergoing clinical testing in various diseases. Major technology alliances include collaborations with Sanofi, Bayer, Alnylam Pharmaceuticals, and Intellia Therapeutics. In FY2025, the company’s R&D expenses amounted to US$5,214 million, which as a percentage of revenue stood at 36.4%. As of December 2025, the company had 15 medicines approved in the US or other countries.
Product Categories
- Collaboration Revenue
- Evkeeza-US
- Inmazeb-US
- Other Revenue
- Praluent-US
- Total Eylea HD and Eylea-US
- Total Libtayo–Global
Overview
Includes the company's share of profits or losses in connection with the commercialization of products; reimbursement for manufacturing of commercial supplies; and royalties or sales-based milestones earned.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Evkeeza in the US. Evkeeza (evinacumab) is a drug used to treat homozygous familial hypercholesterolemia (HoFH) in adults, adolescents, and pediatrics.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Inmazeb in the US. Inmazeb (atoltivimab, maftivimab, and odesivimab) is a drug to treat infection caused by Zaire ebolavirus.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes the net product sales of Praluent outside the US, which are paid to the company by Sanofi as a royalty on such sales.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Praluent in the US. Praluent (alirocumab) is a drug used to treat LDL-lowering in heterozygous familial hypercholesterolemia (HeFH); atherosclerotic cardiovascular disease (ASCVD); HeFH in pediatrics and adolescents (8–17 years of age); cardiovascular risk reduction in patients with established cardiovascular disease; and homozygous familial hypercholesterolemia (HoFH).
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers products including Eylea HD and Eylea. Eylea HD and Eylea (aflibercept) 8 mg is a soluble fusion protein that functions as a vascular endothelial growth factor (VEGF) inhibitor. It is specifically formulated to provide a concentrated dose of aflibercept to obstruct VEGF-A and PLGF, thereby inhibiting the formation of new blood vessels and reducing vascular permeability. This treatment is used for various retinal diseases, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). Eylea HD is distributed in the US, and Eylea is distributed in other countries.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Libtayo in the US and other countries. Libtayo (cemiplimab) is a fully human monoclonal antibody that targets the PD-1 immune checkpoint receptor on T-cells. The PD-1/PD-L1 immune checkpoint pathway is recognized as a mechanism through which cancers can avoid being attacked by the immune system.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer